Haotian Dong
Chengyuan Ye
Xuan Yu
Yongfu Shao- 1Department of Gastroenterology, the First Affiliated Hospital of Ningbo University, Ningbo, China
- 2Health Science Center, Ningbo University, Ningbo, China
Gastric cancer immunotherapy, recognized as the fourth primary treatment modality after surgery, radiotherapy, and chemotherapy, encompasses strategies such as immune checkpoint inhibitors and cellular immunotherapy and provides new avenues for cancer control. Recent studies have revealed that non-coding RNAs (ncRNAs), including miRNAs, lncRNAs, piRNAs, siRNAs, and circRNAs, drive the progression of gastric cancer primarily through three regulatory axes: epigenetic modification, transcriptional reprogramming, and tumor microenvironment remodeling. These processes are closely linked to tumor immunity and the efficacy of immunotherapy in gastric cancer (GC). Building on an overview of current immunotherapy regimens for GC, this review provides a comprehensive summary of the molecular mechanisms by which ncRNAs regulate immune cell infiltration, modulate immune checkpoints, and reshape the immunosuppressive microenvironment to influence immunotherapeutic outcomes. Furthermore, the potential translational applications of ncRNAs as prognostic biomarkers and therapeutic targets within the context of GC immunology are discussed. Collectively, these mechanistic insights and clinical perspectives offer a theoretical foundation for overcoming the limitations of current immunotherapy approaches and improving the long-term prognosis of patients with GC.
1 Introduction
According to the 2025 Global Cancer Statistics released by the International Agency for Research on Cancer (IARC) Global Cancer Observatory (GLOBOCAN), gastric cancer ranks fifth in both global cancer incidence and mortality (1). Notably, East Asian countries account for a disproportionately high incidence rate of 71.4%, a striking epidemiological disparity attributed to region-specific risk factors, including distinct dietary patterns, the prevalence of Helicobacter pylori infection, and population-specific genetic susceptibilities (2). Although the widespread adoption of endoscopic screening has improved early detection rates, the insidious onset and aggressive nature of gastric cancer result in most patients being diagnosed at advanced stages, contributing to a persistently poor 5-year survival rate of less than 30% (3). Advances in immuno-oncology and tumor microenvironment (TME) research have identified tumor immune escape mechanisms as critical therapeutic targets (4, 5). Cancer cells orchestrate immunosuppression by dysregulating T-cell effector functions and overexpressing immune checkpoint molecules while simultaneously evading immune surveillance through selective loss of highly immunogenic antigens (6). Emerging evidence positions immunotherapy as a promising treatment option for advanced gastric cancer. Although immune checkpoint inhibitors offer superior prognostic outcomes compared to conventional therapies by reactivating the host immune response against tumor cells, the heterogeneity of the TME contributes to therapeutic resistance, posing a significant clinical challenge (7, 8). This therapeutic paradox underscores the urgent need to elucidate the molecular determinants of immunotherapy responsiveness in gastric cancer.
Non-coding RNAs (ncRNAs) are a class of RNA molecules that are not translated into proteins and exhibit dynamic expression patterns in human cells. These include miRNA, lncRNA, circRNA, siRNA, and piRNA, whose abundance and regulatory functions profoundly influence cellular homeostasis (9, 10). Molecular biology studies have revealed that specific ncRNAs perform distinct biological roles through complex interactome networks (11), such as modulating mRNA translation via RNA-binding proteins (RBPs), regulating gene expression as competing endogenous RNAs (ceRNAs), and fine-tuning critical signaling pathways (12, 13). Recent foundational research has demonstrated that various non-coding RNA subtypes regulate gene expression in gastric cancer through epigenetic, transcriptional, and post-transcriptional mechanisms, thereby contributing to tumorigenesis and influencing tumor immunity (14, 15).
This review provides a comprehensive overview of the biological functions of ncRNAs and current immunotherapeutic strategies for gastric cancer. This review highlights specific ncRNAs that modulate downstream targets affecting the tumor immune response by regulating immune cell infiltration, altering immune checkpoint expression, and remodeling the immunosuppressive microenvironment. At the clinical level, ncRNAs hold potential as biomarkers for predicting immunotherapy outcomes and as therapeutic targets, offering precise strategies for intervention in gastric cancer treatment.
2 Overview of ncRNAs
2.1 Concept and types of ncRNAs
NcRNAs are ubiquitous in eukaryotic organisms and directly regulate cellular processes at the post-transcriptional level (16). Unlike messenger RNAs (mRNAs), which serve as carriers of genetic information, ncRNAs regulate various cellular functions through various mechanisms, including gene expression modulation, chromatin remodeling, RNA splicing, and translational control (17). Groundbreaking genomic studies have redefined conventional understanding: although only about 2% of the human genome encodes proteins, recent data from the ENCODE project reveal that over 76% of genomic DNA is actively transcribed into ncRNAs. These ncRNAs display tissue-specific expression patterns and are highly responsive to disease states (18). The advent of high-throughput sequencing technologies has further illuminated the crucial role of ncRNAs in tumorigenesis (19). For example, lncRNA H19, which is abnormally expressed in gastric cancer, influences the infiltration of cancer-associated fibroblasts (CAFs), macrophages, CD4+T cells, and CD8+T cells in the TME through the miR-378a-5p/SERPINH1 axis, thereby promoting the progression of gastric cancer (20). These findings underscore the strategic significance of ncRNAs in cancer immunotherapy and highlight their potential in the development of RNA interference-based targeted therapies.
NcRNAs are broadly classified into small non-coding RNAs (sncRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), based on their molecular length and functional characteristics (21). The sncRNA category primarily includes microRNAs (miRNAs), small interfering RNAs (siRNAs), and PIWI-interacting RNAs (piRNAs) (21). miRNAs, typically 20–25 nt in length, mediate translation inhibition or RNA degradation by partially binding to the 3 ‘-untranslated region (3 ‘-UTR) of target mRNAs, thereby regulating processes such as cell proliferation and apoptosis (22) (Figure 1A). In contrast, siRNAs induce gene silencing by forming perfect complementary base pairs with target mRNAs, resulting in mRNA degradation and the suppression of homologous gene expression (23) (Figure 1B). Leveraging this gene-silencing mechanism, siRNA-based technologies are now being incorporated into the development of immune checkpoint blockade therapies (24). piRNAs, 24–31 nucleotides in length, are germ cell-specific ncRNAs that associate exclusively with PIWI protein family members to form piRNA-PIWI complexes, which are essential for maintaining genomic stability and regulating translation (25) (Figure 1C). lncRNAs are defined as RNA transcripts longer than 200 nucleotides (26, 27) and are predominantly transcribed by RNA polymerase II (Pol II) (28) (Figure 1D). CircRNAs are mainly produced by RNA Pol II transcription. They characterized by their covalently closed loop structures, possess distinct regulatory functions by acting as molecular sponges that sequester miRNAs or by interacting with RNA-binding proteins (29, 30) (Figure 1E). Together, these ncRNA classes function as a complex “RNA regulatory code” with critical implications for advancing precision medicine.
Figure 1. Classification of ncRNAs. (A) miRNAs are ncRNAs with a length of 20–25 nt, generated through Dicer, TRBP, and AGO-mediated cleavage of pre-miRNA. They function by binding to target mRNAs in a sequence-specific manner, resulting in either transcript degradation or translational repression. (B) siRNAs, approximately 20–25 nt in length, are produced by Dicer-mediated dsRNA cleavage and are composed of a guide strand and a passenger strand. (C) piRNAs, measuring 26-31nt, associate with PIWI proteins. Primary piRNAs undergo Zuc-dependent cleavage to generate mature piRNAs, which are subsequently methylated at the 3′-end. (D) LncRNAs are transcripts over 200 nt in length, typically synthesized by RNA polymerase II. (E) CircRNAs are covalently closed circular RNA molecules, generally 200-2000nt in length.
2.2 The biological functions of ncRNAs
ncRNAs have emerged as critical regulators of various biological processes. Their functions extend beyond epigenetic modification, transcriptional, and post-transcriptional regulation to include complex roles in TME remodeling (31). Mechanistic studies have shown that distinct ncRNA subtypes drive gastric cancer progression through specific molecular interaction networks, profoundly impacting clinical outcomes and prognosis (32).
At the epigenetic regulation level, lncRNAs dynamically shape the epigenetic landscape by recruiting chromatin-modifying complexes (Figure 2A). For example, the oncogenic lncRNA linc01503 in gastric cancer interacts with zeste homolog 2 (EZH2) and lysine (K)-specific demethylase 1A (LSD1) enhancers, targeting the promoter regions of dual-specificity phosphatase 5 (DUSP5) and cyclin-dependent kinase inhibitor 1A (CDKN1A). This interaction induces histone H3 lysine 27 trimethylation (H3K27me3), leading to the epigenetic silencing of these tumor suppressor genes. Such epigenetic reprogramming inactivates cell cycle checkpoints, thereby enhancing the oncogenic potential of gastric cancer cells (32). In contrast, the tumor-suppressive lncRNA MEG3 exerts its function through a different epigenetic mechanism. miR-148 inhibits the translation of DNA methyltransferase 1 (DNMT1), thereby reversing hypermethylation at the MEG3 promoter. This reactivation restores MEG3 expression and suppresses gastric cancer progression (33).
Figure 2. Biological functions of ncRNAs in gastric cancer. (A) Epigenetic regulation: LincRNA1503 recruits EZH2 and LSD1 to the promoter regions of DUSP5 and CDKN1A, inducing histone methylation that silences these tumor-suppressor genes and promotes the proliferation of gastric cancer cells. MiR-148a binds to DNMT1, reversing the hypermethylation of the MEG3 promoter and restoring the expression of this tumor-suppressive lncRNA, thereby inhibiting gastric carcinogenesis. (B) Post-transcriptional control: Circ-hnRNPU interacts with the NONO protein to suppress c-Myc transcription, thereby reducing the glycosylation of surface proteins in gastric cancer cells. LncRNA MEF forms a complex with hnRNPK, enhancing the translational efficiency of c-Myc mRNA and amplifying the oncogenic MEF-c-Myc feedback loop. MiR-135b-5p targets CLIP4, attenuating the JAK2/STAT3 signaling pathway and facilitating tumor proliferation. CircRNA_0051246 competitively binds miR-375, derepressing the proto-oncogene YAP and accelerating gastric cancer progression. (C) Tumor microenvironment modulation: Exosomal miR-92b-5p, internalized by TAMs, disrupts SOCS7-STAT3 binding, activating STAT3 signaling to drive M2 polarization and promote gastric cancer growth. SP1-activated lncRNA AGAP2-AS1 recruits LSD1 and EZH2 to repress E-cadherin transcription, impairing intercellular adhesion and facilitating tumor dissemination.
Post-transcriptional regulation represents a central molecular mechanism by which ncRNAs drive oncogenesis through modulation of mRNA stability, translational efficiency, and protein function dynamics (34–36) (Figure 2B). For instance, circ-hnRNPU, which is downregulated in gastric cancer cells, binds to the NONO protein and competitively inhibits its interaction with the 3′-UTR of c-Myc mRNA. This dual mechanism suppresses c-Myc transcription and destabilizes its mRNA, thereby impeding abnormal glycosylation of surface proteins in gastric cancer cells (37). In colorectal cancer, the overexpression of lncRNA MEF enhances c-Myc mRNA translational efficiency by interacting with heterogeneous nuclear ribonucleoprotein K (hnRNPK), establishing the MEF-c-Myc regulatory axis as a driver of tumorigenesis (38). Similarly, the upregulation of miR-135b-5p in gastric cancer promotes tumor invasiveness by targeting CLIP4, thereby impairing the tumor-suppressive JAK2/STAT3 signaling pathway (39). The molecular sponge function of circRNAs is particularly prominent in post-transcriptional regulation. CircRNA_0051246, enriched with miR-375 binding sites, competitively sequesters miR-375, preventing it from silencing the proto-oncogene YAP1. This axis increases YAP protein levels, promoting self-renewal of cancer stem cells and accelerating gastric cancer progression (40).
In the context of TME remodeling, exosome-derived ncRNAs facilitate immune suppression via intercellular communication (Figure 2C). Gastric cancer cells secrete miR-92b-5p in exosomes, which are taken up by tumor-associated macrophages (TAMs). There, miR-92b-5p disrupts the SOCS7-STAT3 interaction, activating STAT3 signaling and inducing the M2 polarization of TAMs, which in turn promotes the proliferation of gastric cancer cells (41). Furthermore, the oncogenic lncRNA AGAP2-AS1, which is transcriptionally activated by SP1 in gastric cancer cells, forms a complex with LSD1 and EZH2 to repress E-cadherin mRNA expression. This repression reduces cell-cell adhesion and triggers epithelial-mesenchymal transition (EMT) (42).
3 Current advances in immunotherapeutic regimens for gastric cancer
3.1 Immune checkpoint inhibitors
While conventional therapeutic approaches offer limited survival benefits in gastric cancer, the persistently poor prognosis underscores the urgent need for more effective treatment strategies. The advent of ICI therapy has revolutionized the management of advanced-stage malignancies, demonstrating superior clinical efficacy in refractory and metastatic tumors compared with traditional treatments (43, 44). Mechanistically, immune checkpoints facilitate tumor immune evasion by engaging specific ligands that attenuate T-cell activity. ICIs disrupt this immunosuppressive pathway by targeting checkpoint molecules, thereby restoring T-cell-mediated antitumor responses (45) (Figure 3A). Currently, U.S. FDA-approved ICIs are classified into two major categories based on their molecular targets: programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors (e.g., nivolumab, pembrolizumab, and durvalumab) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (e.g., ipilimumab and tremelimumab) (46). Recent clinical trials have rigorously evaluated the efficacy of ICIs in advanced gastric cancer. In the ATTRACTION-2 trial, Kang et al. demonstrated that nivolumab combined with chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy alone (OS: 5.26 vs 4.14 months; HR = 0.63, p<0.0001) (47). Similarly, the KEYNOTE-859 trial led by Sun et al. showed that pembrolizumab plus chemotherapy resulted in a 1.4-month OS improvement over standard chemotherapy (median OS: 12.9 vs. 11.5 months; HR = 0.78, p<0.0001), establishing this combination as a new standard of cure (48). These paradigm-shifting outcomes have redefined the therapeutic landscape of advanced gastric cancer, advancing the field toward precision immuno-oncology.
Figure 3. Molecular mechanisms of immunotherapies in gastric cancer. (A) PD-L1 regulation by cytokines: Tumor cell surface PD-L1 expression is upregulated by T cell-derived cytokines (e.g., IFN-γ, ILs) through SHP-2-mediated signaling. Anti-PD-1 antibodies block this axis by binding PD-1, thereby reducing PD-L1 expression and inhibiting tumor immune evasion. (B) Pharmacologic disruption of PD-L1 function: The agent targets PD-L1 through distinct mechanisms; for example, BMS-202 impairs dimerization, CSN5 inhibits ubiquitination, and tomivosertib suppresses synthesis. Collectively, these actions prevent the engagement of PD-L1/PD-1. (C) CAR-T therapy targeting HER2: CAR-T cells directed against HER2 epitopes effectively suppress gastric cancer progression, although treatment may cause mucositis. (D) CT041 targeting CLDN18.2: CT041 specifically targets the CLDN18.2 antigen, allowing for the selective elimination of tumor cells. (E) CTLA-4 pathway blockade: CTLA-4 on regulatory T cells (Tregs) binds CD80/CD86 on antigen-presenting cells (APCs), initiating endocytosis that depletes costimulatory ligands and inhibits CD28 signaling. Anti-CTLA-4 antibodies (ipilimumab and tremelimumab) block this interaction, suppressing tumor growth despite potential adverse effects such as nausea and vomiting. (F) CIK cells mediate tumor cell apoptosis via multiple mechanisms: the release of cytotoxic molecules such as perforin, granzyme B, CD3 and CD56, and the engagement of Fas ligand on CIK cells with Fas receptors on tumor cells.
Programmed death 1 (PD-1), an immunosuppressive receptor predominantly expressed on T-cells (49), binds to its principal ligand, programmed death ligand 1 (PD-L1), which is frequently overexpressed in malignant tumors—particularly in advanced gastric cancer associated with Epstein-Barr virus (EBV) (50, 51). Upon PD-1 binding to PD-L1, the phosphatase SHP-2 is recruited, resulting in the disruption of downstream T-cell receptor signaling. Consequently, T-cell activation is suppressed, thereby inhibiting the production of cytokines such as interferon-γ (IFN-γ) and interleukins (ILs). This pathway sustains immune tolerance and facilitates tumor immune escape (52, 53). Targeting the PD-1/PD-L1 axis has become a central focus in cancer immunotherapy, with monoclonal antibodies (mAbs) such as pembrolizumab and nivolumab receiving FDA approval since 2014 (54, 55). However, conventional mAb-based therapies face limitations, including inadequate tumor penetration (56) and systemic adverse effects such as gastrointestinal toxicity, endocrine dysregulation, and dermatologic reactions (57). These limitations have spurred interest in small-molecule inhibitors targeting the PD-1/PD-L1 pathway. BMS-202, a non-peptidic compound, disrupts PD-1/PD-L1 interaction by inducing PD-L1 dimerization (58) (Figure 3B). Complementing this extracellular targeting approach, eFT508 (Tomivosertib) acts at the translational level by inhibiting phosphorylation of eukaryotic initiation factor 4E (eIF4E) at Ser209, thereby reducing PD-L1 protein synthesis in gastric cancer organoids (59) (Figure 3B). Additionally, curcumin mediates post-translational PD-L1 regulation by promoting its ubiquitination via the COP9 signalosome subunit 5 (CSN5), which accelerates PD-L1 degradation (60) (Figure 3B).
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), a ligand-independent immune checkpoint, plays a critical role in regulatory T cell (Treg)-mediated immunosuppression (61) (Figure 3E). Patients with gastric cancer exhibit significantly elevated Treg levels compared to healthy individuals, with Treg infiltration increasing across tumor stages, an indicator of poor prognosis. CTLA-4, expressed on Tregs, binds to CD80 and CD86 ligands on antigen-presenting cells (APCs), triggering the internalization of the CTLA-4 complex. This endocytosis depletes costimulatory ligands from the APC surfaces, inhibiting CD28-mediated T-cell activation and facilitating systemic immune suppression (62). Clinically approved anti-CTLA-4 monoclonal antibodies (mAbs), including ipilimumab and tremelimumab, have demonstrated varied efficacy profiles. In melanoma, ipilimumab significantly improves overall survival and progression-free survival compared with PD-1/PD-L1 inhibitors (63), although this benefit is associated with a 5% higher incidence of immune-related adverse events (64). In contrast, trials in gastrointestinal cancers have reported limited efficacy of tremelimumab in metastatic gastric and esophageal cancers, along with severe toxicities including nausea, vomiting, and rare cases of bowel perforations (65). These findings underscore the need for the development of next-generation CTLA-4 inhibitors that strike a balance between therapeutic effectiveness and improved safety.
3.2 Immunotherapy for cellular cancer
Tumor cells secrete immunosuppressive cytokines, such as interleukin-10 (IL-10), prostaglandin E2, and lymphocyte-activation gene 3 (LAG-3), thereby promoting immune evasion (66). Cellular immunotherapy is a transformative therapeutic approach in which autologous immune cells are genetically engineered to acquire tumor-specific recognition and cytotoxic capabilities (67). In gastric cancer, two primary cellular immunotherapeutic strategies have emerged as mainstays in clinical practice: adoptive cell therapy (ACT) and tumor vaccine-based approaches (68). These therapies activate tumor-specific cytotoxic T lymphocytes (CTLs) to lyse tumor cells and neutralize malignant cells by targeting surface antigens (69). The identification of multiple gastric cancer-associated tumor antigens has enabled the development of next-generation regimens for advanced disease, facilitating precision immunotherapies that enhance tumor immunogenicity while mitigating immune tolerance.
Adoptive cell therapy (ACT) involves isolating, modifying, and reinfusing a patient’s immune cells to directly kill tumor cells or amplify antitumor immune responses (70). Current ACT strategies employ various immune cell types, including tumor-infiltrating lymphocytes (TILs), cytokine-induced killer (CIK) cells, and chimeric antigen receptor (CAR) T cells (71, 72). TILs, which comprise heterogeneous populations of T cells, B cells, and natural killer (NK) cells, reflect the immune reactivity of the host to tumors (73). Clinical studies in advanced gastric cancer indicate that high TIL infiltration serves as an independent prognostic marker for overall survival, and is associated with prolonged OS (49, 74). CIK cells, characterized by dual CD3+CD56+ membrane expression and rapid ex vivo expansion, demonstrate potent tumoricidal activity (75, 76) (Figure 3F). In a phase II trial of metastatic gastric cancer, CIK cell infusion combined with FOLFOX4 chemotherapy significantly improved the objective response rates and quality-of-life scores (77). Similarly, intraperitoneal CIK administration with chemotherapy reduced the volume of malignant ascites and extended median OS in patients with gastric cancer with peritoneal carcinomatosis without increasing toxicity (78). As key mediators of tumor immunosurveillance, NK cells play a crucial role in suppressing gastric cancer progression and metastasis. Ishigami et al. conducted a retrospective analysis of 146 gastric cancer specimens and found that high NK cell infiltration was associated with lower TNM stage, reduced lymphovascular invasion, and improved five-year survival (79). Despite promising results, ACT in gastric cancer requires further optimization, including the development of standardized cell expansion protocols, optimization of dosing regimens, and strategies to mitigate cytokine release syndrome (CRS) in CAR-T therapy (80).
CAR-T therapy, a leading form of ACT, has been extensively used in refractory and recurrent solid tumors (81). This approach involves genetically modifying patients’ T cells to express chimeric antigen receptors (CARs) (82), enabling MHC-independent tumor recognition and cytotoxic activity against antigen-expressing cancer cells (83). Human epidermal growth factor receptor 2 (HER2), which is frequently overexpressed in gastric cancer, has been targeted in CAR-T trials, resulting in partial remission and an improved prognosis (Figure 3C). However, dermatitis and mucositis have been reported as adverse effects (84). Claudin 18.2 (CLDN18.2), a tight junction protein highly expressed in gastric adenocarcinomas and metastases (85), has emerged as another promising target. In preclinical models, CLDN18.2-specific CAR-T cells inhibited tumor growth with favorable safety profiles (86). Satricabtagene autoleucel (satri-cel, CT041), a first-in-class CLDN18.2-targeted CAR-T therapy, is currently undergoing global clinical trials (Figure 3D). In a phase I study, Qi et al. reported an objective response rate (ORR) of 57.1% and a disease control rate (DCR) of 75%, with a six-month OS rate of 81.2% in gastric cancer patients (87). By comparison, third-line treatments, such as nivolumab, pembrolizumab, trifluridine/tipiracil, and apatinib, yield ORRs of 11.2%, 13.3%, 4%, and 1.7%, respectively, with median OS below six months (47, 88–90). These results position CT041 as a potentially transformative option in third-line gastric cancer therapy, showing superior efficacy to conventional regimens in refractory advanced or metastatic disease (91). Mechanistically, Samer et al. demonstrated that anti-mesothelin hYP218 CAR-T cells persisted within the tumor microenvironment and retained cytotoxicity, with the co-administration of pembrolizumab enhancing antitumor activity in advanced gastric cancer (92). Beyond HER2 and CLDN18.2, emerging CAR-T targets include mesothelin (MSLN), carcinoembryonic antigen (CEA), and epithelial cell adhesion molecule (93).
Despite substantial advances, cellular immunotherapy in gastric cancer still faces challenges such as high treatment costs and unresolved safety concerns. Current research focuses on next-generation CAR-T platforms with enhanced tumor specificity and multimodal regimens combining cellular therapies with complementary treatments. These strategies aim to enhance the efficacy, safety, and cost-effectiveness of gastric cancer management.
4 The molecular mechanism of ncRNAs in gastric cancer immunotherapy
4.1 Regulation of immune cell infiltration
NcRNAs act as central regulators of the gastric cancer tumor microenvironment, orchestrating immune cell infiltration and antitumor immune responses through epigenetic reprogramming, modulation of signaling pathways, and RNA-RNA/protein interaction networks (Table 1). These molecular regulators influence the recruitment, activation, and functional polarization of cytotoxic T lymphocytes (CTLs), regulatory T cells (Tregs), tumor-associated macrophages (TAMs), and myeloid-derived suppressor cells (MDSCs) (94). ncRNAs function as molecular hubs to maintain the balance among immune cell subpopulations (Figure 4A). For example, by suppressing NF-κB signaling, NKILA reduces the susceptibility of T cells to activation-induced cell death (AICD), thereby enhancing their antitumor capacity. However, clinical data indicate that gastric cancer patients with high NKILA expression in tumor-specific CTLs have shorter median overall survival than those with low expression, suggesting that lncRNA-based therapies may exert tumor microenvironment-specific effects and require further profiling for precision application (95). Conversely, circ_0008287, which is overexpressed in gastric tumors, promotes immune evasion by sponging miR-548c-3p to derepress chloride intracellular channel 1 (CLIC1). This axis impairs CD8+ T-cell function, reduces IFN-γ secretion, and accelerates tumor progression (96). FOXP3 is significantly overexpressed in gastric cancer tissues compared with adjacent normal mucosa (97). Tumor-associated FOXP3 competitively binds NF-κB p65, reducing its transcriptional activation of the tumor suppressor p21 and promoting cancer cell proliferation (98). The tumor-suppressive miR-34a, which is transcriptionally regulated by megakaryocytic leukemia 1 (MKL1), directly targets FOXP3 mRNA, thereby limiting Treg differentiation and its tumor-promoting effects (99). Similarly, miR-133a-3p binds to FOXP3, suppressing its expression and stimulating autophagy in gastric cancer cells, thereby contributing to the stability of the tumor microenvironment (100). miR-128-3p has been identified as a master immunoregulator that controls IL-16-dependent recruitment of CD4+CD25+FOXP3+ Tregs, thereby dampening antitumor immunity (101). These findings suggest that miRNA-mediated regulation of TIL subsets represents a potential direction for the development of tumor immunotherapy. Compared to adjacent tissues, gastric cancer lesions contain significantly more FOXP3+ Tregs. The cyclooxygenase-2 (COX-2) released by these cells induces the expression of prostaglandin E2, which suppresses the activity of effector T cells, providing an additional mechanism for immune evasion (102). Therefore, COX-2 inhibitors may reduce COX-2 expression and enhance effector T-cell function, offering another avenue for gastric cancer immunotherapy.
Table 1. Molecular mechanisms of ncRNAs in gastric cancer immunotherapy.
Figure 4. Molecular mechanisms of ncRNAs in gastric cancer immunotherapy. (A) Immune cell infiltration modulation: LncRNA NKILA suppresses T cell apoptosis and tumor proliferation by inhibiting the NF-κB pathway. Circ_0008287 binds to miR-548c-3, relieving its inhibition of CLIC1 and thereby promoting immune cell apoptosis and accelerating tumor progression. MiR-34a interacts with MKL1 to repress FOXP3, facilitating tumor cell proliferation. CircATP8A1 enhances STAT6-mediated M2 macrophage polarization by sponging miR-1-3p. Conversely, EGCG inhibits STAT3-dependent PLXNC1 expression, reducing miR-92b-5p levels and suppressing M2 polarization. Exosomal miR-552-5p represses NKG2D and NKp46 transcription, thereby impairing NK cell cytokine production (IFN-γ, TNF-α, perforin, and granzyme B). IL-2-stimulated NK cells downregulate GAS5 lncRNA expression. (B) Immune checkpoint regulation: CircRHBDD1 stabilizes PD-L1 mRNA expression via IGF2BP2. Hsa_circ_0136666 relieves miR-375-mediated suppression of PRKDC by enhancing PD-L1 phosphorylation. Collectively, these mechanisms elevate PD-L1 expression, promoting immune evasion. LncRNAs (NUTM2A-AS1/miR-376a, SNHG15/miR-141, and PROX1-AS1/miR-877-5p) upregulate PD-L1 to accelerate the progression of gastric cancer. In contrast, lncRNA LOC339059 inhibits c-Myc-dependent IL-6 transcription, thereby suppressing STAT3 phosphorylation and PD-L1 activation, ultimately impairing macrophage polarization and the activation of gastric cancer cells. (C) Tumor microenvironment reprogramming: In tumor angiogenesis, the lncRNA CRART16/miR-122-5p axis activates FOS-mediated VEGF/VEGFR2 signaling. MiR-23a promotes PI3K/Akt activation by targeting PTEN. Exosome-transferred miR-519a-3p induces DUSP2/MAPK/ERK-mediated M2 polarization, triggering the secretion of pro-angiogenic cytokines (TGF-β, VEGFA, VEGFD). In extracellular matrix remodeling, lncRNA HOTAIR and miR-29a-3p modulate COL5A1 expression, with the overexpression of HOTAIR promoting collagen deposition and ECM stiffening, while miR-29a-3p counteracts this effect. ECM stiffening impairs immune cell infiltration and facilitates tumor proliferation. In addition, USP7 deubiquitinates hnRNPA1 in CAFs, enabling the transfer of exosomal miR-522 to tumor cells, where it inhibits ALOX15, reduces lipid-ROS production, and suppresses ferroptosis. COX-2/HIF-1α-activated miRNA-205 induces IL-6 secretion and promotes EMT progression. MiR-192-5p activates RB1/NF-κBp65 signaling, thereby enhancing IL-10 secretion and regulating Treg differentiation and EMT.
Within the immunosuppressive tumor microenvironment, M2-polarized macrophages are critical mediators of immune evasion, with their polarization regulated by ncRNAs via exosome-mediated communication. CircATP8A1, enriched in gastric cancer-derived exosomes, sponges miR-1-3p, depressing STAT6 expression, which drives M2 polarization and accelerates tumor progression (103). Additionally, the natural polyphenol epigallocatechin gallate (EGCG) exerts dual immunomodulatory effects by transcriptionally repressing STAT3, thereby downregulating PLXNC1 expression and reducing exosomal miR-92b-5p levels in gastric cancer cells. In clinical specimens, the STAT3/PLXNC1 axis-regulated miR-92b-5p is strongly correlated with M2 macrophage infiltration (41). These findings establish a mechanistic basis for targeting the STAT3-PLXNC1-miR-92b-5p axis, with EGCG proposed as a potential synergistic partner for immune checkpoint inhibitors to overcome immunotherapy resistance in gastric cancer.
NK cells also play a pivotal role in antitumor immunity. Inflammatory cytokines, such as IL-2, enhance the secretion of TNF-α and IFN-γ by NK cells but downregulate the tumor-suppressive lncRNA GAS5. Luciferase assays confirm direct binding of GAS5 to miR-18a, and GAS5 depletion increases miR-18a expression, thereby reducing NK cell cytotoxicity. Restoring GAS5 levels significantly increases NK cell infiltration in gastric cancer tissues, supporting its potential in NK cell-based immunotherapy (104). Tang et al. described a dual inhibitory mechanism in which exosomal miR-552-5p suppresses the transcription of NK cell activation receptors NKG2D and NKp46, while decreasing the secretion of cytotoxic molecules IFN-γ and TNF-α. Simultaneously, miR-552-5p upregulates PD-L1 expression, thereby activating the PD-1/PD-L1 checkpoint and reducing the secretion of perforin and granzyme B. Notably, the PD-L1 inhibitor durvalumab can counteract the immunosuppressive effects of miR-522-5p, thereby restoring NK cell cytotoxicity. In vivo experiments in nude mice confirmed a significant reduction in tumor volume following treatment with an anti-PD-L1 antibody (105, 106). These results indicate that ncRNAs can induce NK cell exhaustion through a multi-level receptor-ligand-effector regulatory network, offering novel targets for immune checkpoint inhibitors in gastric cancer.
Based on these mechanistic insights, therapeutic strategies that silence oncogenic ncRNAs can restore CTL function, while restoring tumor-suppressive ncRNAs can counteract Treg-mediated immunosuppression. Together, these approaches can remodel the tumor microenvironment into a pro-immunogenic state. The integration of ncRNA modulation with current immunotherapies holds promise for improving response rates and advancing precision immuno-oncology.
4.2 Regulation of the expression of immune checkpoint molecule
The dysregulated expression of immune checkpoint molecules, particularly PD-1/PD-L1 and CTLA-4, represents a key mechanism of immune evasion in gastric cancer (Table 1). NcRNAs have emerged as critical modulators of this process through epigenetic reprogramming and post-transcriptional control (Figure 4B). CircRHBDD1, which is markedly upregulated in gastric cancer tissues, enhances PD-L1 mRNA stability by directly interacting with the RNA-binding protein IGF2BP2 in an m6A-dependent manner. This interaction increases PD-L1 protein levels and reduces CD8+ T-cell infiltration, thereby promoting tumor immune escape. Targeted delivery of circRHBDD1-specific siRNA via PLGA-PEG nanoparticles significantly suppressed tumor growth, enhanced the efficacy of anti-PD-L1 therapy, and reduced severe adverse effects in murine models (107). Similarly, miR-375, which is downregulated in gastric cancer, is inversely correlated with PD-L1 expression. Mechanistic analyses indicate that miR-375 inhibits PD-L1 transcription by suppressing JAK2/STAT3 signaling, as evidenced by reduced phosphorylated STAT3 levels following miR-375 overexpression (108). These findings provide a strong rationale for the development of ncRNA-targeted nanotherapeutics along with immune checkpoint blockade.
Emerging evidence shows that ncRNAs regulate immune checkpoints through multiple molecular pathways in gastric cancer. Hsa_circ_0136666, specifically overexpressed in gastric cancer, acts as a molecular sponge for miR-375. This interaction prevents the miR-375-mediated repression of the catalytic subunit of DNA-dependent protein kinase (PRKDC), triggering PRKDC-dependent phosphorylation of PD-L1 and thereby stabilizing PD-L1, which impairs CD8+ T-cell function. Preclinical studies using lipid nanoparticle (LNP)-encapsulated siRNA against hsa_circ_0136666, combined with anti-PD-L1 therapy, demonstrated synergistic tumor suppression, offering a potential strategy to overcome resistance to immune checkpoint inhibitors (109). In another pathway, lncRNA linc01094 dually regulates PD-L1 and PD-L2 expression by sponging miR-17-5p. Elevated PD-L2 expression in linc01094-high tumors induces M2 macrophage polarization and CD8+ T-cell exhaustion, creating an immunosuppressive niche (110). Similarly, lncRNA NUTM2A-AS1 binds to miR-376a, activating the TET1/HIF-1α axis and increasing PD-L1 expression, which confers cisplatin resistance. Combined treatment with cisplatin and anti-PD-L1 produced superior responses in advanced gastric cancer (111). Conversely, lncRNA SNHG15 promotes immune evasion by sponging miR-141, thereby derepressing PD-L1 translation in cancer stem cells, which correlates with diminished anti-PD-L1 efficacy (112). Similarly, PROX1-AS1 sustains PD-L1 expression by sequestering miR-877-5p, thereby driving tumor progression (113). Collectively, these studies identified PD-L1 as a central hub linking ncRNA networks to immune evasion and therapy resistance. A tumor-suppressive miRNA network can also foster an immunopermissive tumor microenvironment through multi-checkpoint regulation. miR-152, miR-93, and miR-545-5p directly target the 3′-UTRs of PD-L1, TIM-3, and B7-H4, respectively, downregulating their expression in gastric adenocarcinoma cells. This coordinated regulation establishes a multi-target inhibitory framework, suggesting new opportunities for combinatorial immunotherapy to overcome resistance to checkpoint blockade (114–116).
Notably, some ncRNAs demonstrate cross-dimensional regulatory capacity, modulating immune checkpoints and influencing the behavior of immune cells. LncRNA LOC339059 directly binds to c-Myc protein, inhibiting its transcriptional activation of IL-6, thereby preventing STAT3 phosphorylation and downstream PD-L1 expression. Elevated IL-6 expression correlates positively with the M2 macrophage markers CD206 and CD204; thus, LOC339059 overexpression suppresses M2 macrophage polarization through the IL-6/STAT3 axis (117). Conversely, exosomal miR-16-5p from M1 macrophages exerts a dual effect: it suppresses PD-L1 expression to activate T-cell-mediated tumor immunity and promotes repolarization of macrophages toward the M1 phenotype, thereby remodeling the tumor-immune microenvironment (118). These findings reveal that individual ncRNAs can concurrently regulate immune checkpoints and immune cell dynamics, adding complexity to ncRNA-mediated checkpoint networks. Targeting checkpoint-associated ncRNAs may provide novel strategies to overcome resistance to immune checkpoint inhibitors in gastric cancer, thereby supporting the development of stage-specific, precision immunotherapies.
4.3 Participation in the remodeling of the tumor microenvironment
The tumor microenvironment of gastric cancer is a dynamic ecosystem composed of stromal cells, extracellular matrix (ECM), and immunosuppressive mediators (Table 1). NcRNAs orchestrate TME remodeling through diverse mechanisms, including regulation of angiogenesis, ECM stiffening, and intercellular communication, exerting a pervasive influence throughout gastric cancer initiation and progression (Figure 4C).
Tumor angiogenesis, the formation of new blood vessels to supply nutrients and oxygen to malignant cells, is critically regulated by vascular endothelial growth factor-A (VEGF-A) (119). Mechanistically, lncRNA CRART16 acts as a molecular sponge for miR-122-5p, thereby relieving its inhibition of the target gene FOS and activating the VEGF/VEGFR2 axis, which promotes angiogenesis in gastric cancer (120). In parallel, exosomal miR-23a, markedly upregulated in gastric cancer, enhances endothelial cell proliferation and vascularization by targeting PTEN to activate the PI3K/Akt pathway (121). Notably, exosomes from gastric cancer cells with high hepatic metastatic potential are enriched in miR-519a-3p. These vesicles transfer miR-519a-3p to macrophages, thereby driving M2 polarization via the DUSP2/MAPK/ERK axis. Polarized macrophages secrete pro-angiogenic cytokines—including transforming growth factor-beta (TGF-β), VEGFA, and VEGFD—thereby increasing vascular permeability and neovascularization and establishing a nutrient-rich pre-metastatic niche that facilitates hepatic colonization. Thus, miR-519a-3p represents a promising biomarker for predicting hepatic metastasis, and its therapeutic inhibition may disrupt pre-metastatic niche formation (122).
Beyond angiogenesis, ncRNAs play a critical role in regulating extracellular matrix remodeling in gastric cancer. The long non-coding RNA HOTAIR, overexpressed in advanced tumors, promotes ECM stiffening by sponging miR-1277-5p, which derepresses the expression of collagen type V α1 chain (COL5A1), leading to excessive collagen deposition. This stiffened ECM enhances immune cell infiltration and accelerates metastasis in preclinical models (123). Conversely, miR-29a-3p counteracts this process by directly targeting COL5A1, thereby inactivating the Wnt/β-catenin pathway. Sulforaphane (SFA), a dietary isothiocyanate, further amplifies miR-29a-3p activity by promoting precursor miRNA transport to the cytoplasm, as confirmed by RNA immunoprecipitation (124). These findings support a dual-therapy strategy combining miR-29a-3p-loaded nanoparticles with ECM-degrading enzymes (e.g., collagenase) to overcome physical barriers to immunotherapy.
Intercellular communication in gastric cancer plays a crucial role in remodeling the tumor microenvironment. Recent studies have highlighted exosome-mediated ncRNA transfer between tumor cells and cancer-associated fibroblasts (CAFs) mediated (125). For example, CAF-secreted miR-522 binds to 15-lipoxygenase (ALOX15) mRNA, inhibiting lipid peroxidation and reducing ferroptosis in gastric cancer cells. Ubiquitin-specific protease 7 (USP7) enhances miR-522 secretion by deubiquitinating and stabilizing heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1). Interestingly, cisplatin and paclitaxel can elevate ferroptosis levels in gastric cancer cells via the USP7/hnRNPA1/miR-522/ALOX15 axis, thereby enhancing chemosensitivity (126). Similarly, the upregulation of miRNA-106b in CAFs promotes tumor invasion and metastasis by targeting PTEN (127). CAF-derived ncRNAs also regulate EMT. miRNA-205, which is activated by the COX-2/HIF-1α axis, stimulates IL-6 secretion, which promotes CAF-induced EMT and contributes to fibrotic remodeling and immune exclusion within the tumor microenvironment (128). Elevated serum miR-192-5p levels correlate with advanced tumor stage and immunosuppressive phenotype. This miRNA enhances IL-10 secretion in gastric cancer cells by targeting the RB1/NF-κBp65 pathway, thereby facilitating Treg differentiation, regulating EMT, and remodeling the tumor immune microenvironment (129). These multifaceted regulatory roles highlight ncRNAs as promising therapeutic targets for disrupting the pro-tumor microenvironment. Integrating ncRNA modulation with stroma-targeted agents, such as angiogenesis inhibitors or ECM remodeling compounds, may enhance the efficacy of immunotherapy through reprogramming of the tumor microenvironment.
5 Clinical potential of ncRNAs in gastric cancer immunotherapy
5.1 Predictive biomarkers of immunotherapy prognosis
Early diagnosis is a critical determinant of clinical gastric cancer outcomes. Dysregulated ncRNAs in tumor tissues and circulation are closely associated with the remodeling of the immune microenvironment and therapeutic responses, making them promising biomarkers for early detection and prognostic stratification. Common detection methods involve the extraction of RNA from sources such as plasma and tissue samples, followed by reverse transcription and quantitative quantitative reverse transcription polymerase chain reaction (qRT-PCR) to verify the presence of differentially expressed targets. Deng et al. developed an immune-related prognostic model for gastric cancer based on competing endogenous RNA (ceRNA) network analysis, identifying three hub RNAs—lncRNA PVT1, miRNA hsa-miR-130a-3p, and mRNA RECK—through LASSO regression. The resulting risk score, lassoScore, was significantly higher in patients with gastric cancer than in healthy controls and correlated with poorer clinical outcomes. Mechanistic analysis linked high lassoScore to increased infiltration of resting memory CD4+ T cells, M2 macrophages, and resting mast cells. Moreover, RECK expression was associated not only with immune cells, such as CD8 T cells, mast cells, and NK cells, but also with immune checkpoints, including CD244, CD160, and PDCD1 (130). This model provides both molecular biomarkers and a theoretical framework for gastric cancer immunophenotyping and personalized therapy. Similarly, Xu et al. analyzed miRNA-immune gene networks in 389 patients with gastric cancer from The Cancer Genome Atlas (TCGA), identifying nine immune-related miRNAs with prognostic value (131). Multivariate Cox regression and ROC curve analyses classified six miRNAs (miR-125b-5p, miR-99a-3p, miR-145-3p, miR-328-3p, miR-133a-5p, and miR-1292-5p) as tumor suppressors and three (miR-675-3p, miR-92b-5p, and miR-942-3p) as oncogenic drivers. Kaplan-Meier analysis stratified patients into high- and low-risk groups, with the high-risk cohort showing significantly reduced survival. Immune profiling revealed distinct infiltration patterns of CD4+ T cells, macrophages, and dendritic cells, thereby validating these miRNAs as prognostic indicators. Prognostic models based on DNA damage repair-related lncRNAs or 11 m6A-modified lncRNAs have shown that patients with low-risk gastric cancer exhibit lower immune infiltration but improved responsiveness to immune checkpoint inhibitors and reduced therapeutic resistance (132, 133). These findings highlight the value of lncRNA-based models in predicting prognosis, immunotherapy sensitivity, and resistance mechanisms.
Liquid biopsy-based ncRNAs profiling offers a non-invasive platform for the real-time monitoring of gastric cancer progression and therapeutic response. Common liquid biopsy techniques involve the analysis of biomarkers in biofluids such as blood, urine, and saliva. Notably, neutrophil-derived miRNAs (miR-223-3p/miR-425-5p) demonstrated superior diagnostic performance (sensitivity: 77.05%; specificity: 77.51%) compared with conventional biomarkers and outperformed existing biomarkers in predicting metastatic potential and immunotherapy responsiveness (134). Exosomal circRNAs also display exceptional stability and can serve as dynamic biomarkers reflecting the status of the immune microenvironment in real-time (135). For instance, hsa_circ_0072309 modulates tumor immune infiltration via activation of the PI3K-AKT/Ras pathway (136), whereas circMAN1A2 (hsa_circ_0000118) influences gastric cancer progression by inhibiting CTL secretion of cytokines such as TNF-α and IFN-γ (137). Similarly, lncRNAs released into the extracellular environment can be detected in blood or other liquid biopsies (138). Ding et al. evaluated eight immune-related lncRNAs in a prognostic risk model and identified lncRNA RP11-617F23.1 as a key predictor of immune infiltration patterns and clinical outcomes in gastric cancer (139).
5.2 Targets of immunotherapy for gastric cancer
Beyond their established role as prognostic biomarkers, numerous ncRNAs hold substantial therapeutic potential as direct molecular targets in gastric cancer. This potential arises from their differential expression between malignant and adjacent normal tissues, coupled with their critical regulatory roles in tumorigenesis and metastasis. Targeting ncRNAs to reprogram the immunosuppressive tumor microenvironment is emerging as a promising strategy to enhance the efficacy of immunotherapy. For instance, Zheng et al. demonstrated that modulating miR-21 expression in post-gastrectomy patients alleviates surgery-induced Th17/Treg imbalance via PD-L1 axis regulation, suggesting that miR-21 inhibition is a viable therapeutic approach for mitigating postoperative immune dysfunction in advanced gastric cancer (140). Similarly, miR-105-5p, epigenetically regulated through GABRA3-mediated promoter hypomethylation, functions as a tumor suppressor by directly binding to the PD-L1 3’UTR and enhancing CD8+ T-cell cytotoxicity (141). These findings position miR-105-5p as a compelling candidate for immunotherapeutic intervention in gastric cancer.
The covalently closed circular structure and intrinsic RNase resistance of circRNAs confer unique advantages for therapeutic application in gastric cancer. Recent studies on ncRNA-mediated immunomodulation have identified critical circRNA-miRNA regulatory axes (e.g., hsa_circ_0061695 and hsa_circ_0091994) that reprogram the TME via immune cell modulation. Dysregulation of these axes promotes malignant progression by subverting immune surveillance and reshaping the tumor microenvironment. ICI therapy or cell-targeted approaches may counter these effects and reduce drug resistance (142). Furthermore, circRHBDD1 promotes immune evasion by enhancing IGF2BP2-mediated stabilization of PD-L1 transcripts, thereby reducing CD8+ T-cell infiltration in gastric cancer. To disrupt this axis, researchers have developed tumor-targeted nanoparticles based on poly (lactide-co-glycolic acid)-polyethylene glycol (PLGA-PEG) for the precise delivery of circRHBDD1-specific siRNA. This system not only induces tumor-specific immune memory but also acts synergistically with PD-1 inhibitors, demonstrating superior tumor-targeting efficiency (107). These advances underscore the need for advanced delivery systems, such as lipid nanoparticles or siRNA conjugates, to improve the stability and in vivo performance of ncRNA-based therapeutics (143).
5.3 Convergent ncRNA-immunotherapy strategies in gastric cancer
The therapeutic integration of ncRNA modulators with established immunotherapies represents a promising strategy for counteracting immune evasion and achieving durable clinical responses in gastric cancer. For example, combinatorial targeting of hsa_circ_0076092 with PD-1 blockade synergistically disrupts the miR-744-5p/SLC7A5 immunosuppressive axis, resulting in greater tumor growth inhibition than monotherapy (144). However, this strategy has not yet entered clinical trials. Similarly, SHP2 phosphatase activates the ROS/JNK/NFAT4 signaling pathway, upregulating the oncogenic lncRNA SNHG18, which in turn promotes CAR-T cell apoptosis through the miR-211-5p/BRD4 axis (145). These findings suggest that inhibiting SNHG18 expression can enhance the efficacy of CAR-T therapy, offering a novel approach for gastric cancer immunotherapy. CircRNA-based strategies also show considerable therapeutic potential. The ceRNA network orchestrated by circDLG1 increases CXCL12 chemokine expression by sequestering miRNAs, thereby fostering an immunosuppressive niche. Silencing circDLG1 suppresses the proliferation and invasion of gastric cancer cells and reduces resistance to anti-PD-1 therapy, highlighting a multi-ncRNA interplay that could be therapeutically exploited (146).
Chemotherapy and radiotherapy can synergistically enhance ncRNA-mediated antitumor effects through distinct mechanisms. MiR-34a, a tumor suppressor, inhibits the proliferation of gastric cancer cells, and its effect is amplified by oxaliplatin, which induces DNA damage to activate the p53/miR-34a/survivin axis (147). The combination of apatinib and pembrolizumab (Keytruda) modulates the lncRNA CES4/miR-616-5p/DUSP2 axis, inducing apoptosis in gastric cancer cells and providing preclinical evidence for clinical application (148). Radiotherapy sensitization strategies have also been linked to ncRNAs. GAS5, a tumor-suppressive lncRNA, enhances radiosensitivity by promoting DNA damage accumulation via precise regulation of the ATM/p38/MAPK pathway (149). Additionally, circRNA PDSS1 enhances cisplatin sensitivity by sponging miR-515-5p, thereby upregulating integrin alpha-11 (ITGA11) expression (150). Future therapeutic development should prioritize ncRNA-guided adaptive trial designs integrated with artificial intelligence (AI)-driven prediction models to optimize the sequencing of combinatorial treatments. Clinically implementing such rationally engineered regimens has the potential to significantly improve prognosis and increase 5-year survival rates in patients with gastric cancer.
6 Research challenges and future prospects
Gastric cancer remains a major global health burden, ranking among the most prevalent malignancies in both incidence and mortality. Innovating therapeutic strategies remains a critical priority in oncology, particularly given the limitations of current treatments. Immune checkpoint blockade (ICB) therapies targeting PD-1/PD-L1 and CTLA-4 have significantly improved outcomes in certain patient subsets. However, the emergence of secondary resistance—largely driven by immunosuppressive reprogramming within the tumor microenvironment mediated by dysfunctional immune cell infiltration—continues to limit clinical response rates. Consequently, optimization of immunotherapeutic approaches remains a key focus of current clinical research. Recent studies have highlighted the pivotal role of ncRNAs in orchestrating the phenotypic remodeling of immune cells, dynamically reshaping the tumor microenvironment, and modulating the expression of immune checkpoints. However, current understanding is limited to a relatively small number of validated ncRNAs, with over 85% of gastric cancer-associated ncRNAs lacking functional characterization in immunological contexts. Bridging the gap between mechanistic insight and clinical application for these uncharacterized ncRNAs will require systematic, multidimensional investigation.
This review synthesizes current knowledge on the regulatory functions of ncRNAs in gastric cancer immunobiology, with particular emphasis on circRNA-miRNA-mRNA networks that modulate immune cell function and checkpoint molecule expression. The discussion also examines the tripartite interactions between ncRNAs, stromal-immune constituents of the tumor immune microenvironment, and cancer cells, revealing novel mechanisms of immune evasion and therapeutic resistance. Despite their therapeutic potential, the clinical translation of ncRNA-based interventions faces three key challenges. Firstly, off-target effects resulting from the lack of tissue-specific expression. Next, drug resistance arising from intratumoral heterogeneity, and then the absence of efficient and safe in vivo delivery systems. To address these limitations, an integrated roadmap for next-generation ncRNA therapeutics is proposed: First, multimodal integration of single-cell transcriptomics, high-throughput sequencing, and longitudinal liquid biopsy profiling should be employed to map ncRNA dynamics at high resolution across gastric cancer tumor microenvironment subdomains, enabling the identification of context-dependent regulatory nodes. Second, precision-targeted delivery platforms, such as lipid nanoparticle-based or exosome-based systems, should be engineered to improve tissue specificity and bioavailability. Third, artificial intelligence (AI)-driven predictive models should be developed to forecast therapeutic efficacy and identify synergistic effects between ncRNA-targeted agents and existing immunotherapies. Collectively, these strategies can bridge the gap between ncRNA biology and precision immuno-oncology, offering a blueprint to overcome delivery, specificity, and resistance challenges that currently constrain clinical application in gastric cancer.
NcRNAs have emerged as a pivotal frontier in oncology research, driving advances in cancer immunotherapy. Combinatorial approaches that integrate ncRNA modulation with established immunotherapies, including immune checkpoint inhibitors, adoptive cell therapies, and tumor vaccines, have the potential to significantly improve patient outcomes. Although clinical translation remains challenging, the convergence of multidisciplinary technologies and innovative drug development positions ncRNAs as key molecular tools to overcome the current therapeutic plateau. Future research must strengthen the bidirectional translation between basic science and clinical practice to accelerate the development of personalized immunotherapeutic regimens and ultimately improve long-term survival in patients with gastric cancer.
Author contributions
HD: Methodology, Writing – original draft, Investigation, Visualization. CY: Writing – original draft, Methodology, Investigation. XY: Writing – original draft, Visualization, Methodology. YS: Funding acquisition, Conceptualization, Supervision, Writing – review & editing, Project administration.
Funding
The author(s) declare financial support was received for the research and/or publication of this article. This study was supported by grants from the Ningbo Top Medical and Health Research Program (No. 2023020612), the Medical and Health Research Project of Zhejiang Province (No. 2024KY319).
Acknowledgments
Thanks for the technical support by the Core Facilities, Health Science Center, Ningbo University.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, et al. Global cancer observatory: cancer today (version 1.1) . Lyon, France: International Agency for Research on Cancer. Available online at: https://gco.iarc.who.int/today (Accessed February 1, 2025).
2. Thrift AP, Wenker TN, and El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. (2023) 20:338–49. doi: 10.1038/s41571-023-00747-0
3. Hu H, Tsai HJ, Ku H, Lo S, Shan Y, Chang H, et al. Survival outcomes of management in metastatic gastric adenocarcinoma patients. Sci Rep. (2021) 11:23142. doi: 10.1038/s41598-021-02391-z
4. Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. (2019) 18:10. doi: 10.1186/s12943-018-0928-4
5. Li C, Chu Y, Dai H, Xian Q, and Zhu W. KDM4C and GFPT1: potential therapeutic targets for gastric cancer. Discov Med. (2024) 36:2408–20. doi: 10.24976/Discov.Med.202436191.222
6. Miura M, Mizukoshi E, Hashiba T, Kitahara M, Miyashita T, Mochizuki T, et al. Effects of adaptive immune cell therapy on the immune cell profile in patients with advanced gastric cancer. Cancer Med. (2020) 9:4907–17. doi: 10.1002/cam4.3152
7. Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. (2024) 23:92. doi: 10.1186/s12943-024-01990-4
8. Meng W, Huang L, Guo J, Xin Q, Liu J, and Hu Y. Innovative nanomedicine delivery: targeting tumor microenvironment to defeat drug resistance. Pharmaceutics. (2024) 16:1549. doi: 10.3390/pharmaceutics16121549
9. The International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. (2004) 431:931–45. doi: 10.1038/nature03001
10. Mo Q, Qiu Y, Liang Y, Wei Q, Fan X, and Pang W. Exploring long noncoding RNAs and ferroptosis in cancer progression. Life Conflux. (2025) 1:e128. doi: 10.71321/jjrzya36
11. Wang W, Han C, Sun Y, Chen T, and Chen Y. Noncoding RNAs in cancer therapy resistance and targeted drug development. J Hematol Oncol. (2019) 12:55. doi: 10.1186/s13045-019-0748-z
12. Hombach S and Kretz M. Non-coding RNAs: classification, biology and functioning. Adv Exp Med Biol. (2016) 937:3–17. doi: 10.1007/978-3-319-42059-2_1
13. Qiu S, Li B, Xia Y, Xuan Z, Li Z, Xie L, et al. CircTHBS1 drives gastric cancer progression by increasing INHBA mRNA expression and stability in a ceRNA- and RBP-dependent manner. Cell Death Dis. (2022) 13:266. doi: 10.1038/s41419-022-04720-0
14. Cech TR and Steitz JA. The noncoding RNA revolution-trashing old rules to forge new ones. Cell. (2014) 157:77–94. doi: 10.1016/j.cell.2014.03.008
15. Meng W, Guo J, Huang L, Zhang Y, Zhu Y, Tang L, et al. Anoikis-related long non-coding RNA signatures to predict prognosis and immune infiltration of gastric cancer. Bioengineering (Basel). (2024) 11:893. doi: 10.3390/bioengineering11090893
16. Yang J, Rastetter RH, and Wilhelm D. Non-coding RNAs: an introduction. Adv Exp Med Biol. (2016) 886:13–32. doi: 10.1007/978-94-017-7417-8_2
17. He L and Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. (2004) 5:522–31. doi: 10.1038/nrg1379
18. Santosh B, Varshney A, and Yadava PK. Non-coding RNAs: biological functions and applications. Cell Biochem Funct. (2015) 33:14–22. doi: 10.1002/cbf.3079
19. Moreira FC, Sarquis DP, Souza JES, Avelar DS, Araújo TMT, Khayat AS, et al. Treasures from trash in cancer research. Oncotarget. (2022) 13:1246–57. doi: 10.18632/oncotarget.28308
20. Li J, Han T, Wang X, Wang Y, Chen X, Chen W, et al. H19 may regulate the immune cell infiltration in carcinogenesis of gastric cancer through miR-378a-5p/SERPINH1 signaling. World J Surg Oncol. (2022) 20:295. doi: 10.1186/s12957-022-02760-6
21. Sana J, Faltejskova P, Svoboda M, and Slaby O. Novel classes of non-coding RNAs and cancer. J Transl Med. (2012) 10:103. doi: 10.1186/1479-5876-10-103
22. O’Brien J, Hayder H, Zayed Y, and Peng C. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). (2018) 9:402. doi: 10.3389/fendo.2018.00402
23. Kawasaki H, Taira K, and Morris KV. siRNA induced transcriptional gene silencing in mammalian cells. Cell Cycle. (2005) 4:442–8. doi: 10.4161/cc.4.3.1520
24. Choi Y, Seok SH, Yoon HY, Ryu JH, and Kwon IC. Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade. Adv Drug Delivery Rev. (2024) 209:115306. doi: 10.1016/j.addr.2024.115306
25. Luteijn MJ and Ketting RF. PIWI-interacting RNAs: from generation to transgenerational epigenetics. Nat Rev Genet. (2013) 14:523–34. doi: 10.1038/nrg3495
26. Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, and Johnson R. Towards a complete map of the human long non-coding RNA transcriptome. Nat Rev Genet. (2018) 19:535–48. doi: 10.1038/s41576-018-0017-y
27. Fang S, Zhang L, Guo J, Niu Y, Wu Y, Li H, et al. NONCODEV5: a comprehensive annotation database for long non-coding RNAs. Nucleic Acids Res. (2018) 46:308–14. doi: 10.1093/nar/gkx1107
28. Wu H, Yang L, and Chen LL. The diversity of long noncoding RNAs and their generation. Trends Genet. (2017) 33:540–52. doi: 10.1016/j.tig.2017.05.004
29. Liu Z, Zhou Y, Liang G, Ling Y, Tan W, Tan L, et al. Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. Cell Death Dis. (2019) 10:55. doi: 10.1038/s41419-018-1287-1
30. Du W, Fang L, Yang W, Wu N, Awan M, Yang Z, et al. Induction of tumor apoptosis through a circular RNA enhancing Foxo3 activity. Cell Death Differ. (2017) 24:357–70. doi: 10.1038/cdd.2016.133
31. Li Y. Non-coding RNA performs its biological function by interacting with macromolecules. Int J Mol Sci. (2023) 24:16246. doi: 10.3390/ijms242216246
32. Tang X, Guo T, Gao X, Wu X, Xing X, Ji J, et al. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. Mol Cancer. (2021) 20:99. doi: 10.1186/s12943-021-01396-6
33. Ma Z, Gao X, Shuai Y, Wu X, Yan Y, Xing X, et al. EGR1-mediated linc01503 promotes cell cycle progression and tumorigenesis in gastric cancer. Cell Prolif. (2021) 54:e12922. doi: 10.1111/cpr.12922
34. Yan J, Guo X, Xia J, Shan T, Gu C, Liang Z, et al. MiR-148a regulates MEG3 in gastric cancer by targeting DNA methyltransferase 1. Med Oncol. (2014) 31:879. doi: 10.1007/s12032-014-0879-6
35. Orom UA, Nielsen FC, and Lund AH. MicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell. (2008) 30:460–71. doi: 10.1016/j.molcel.2008.05.001
36. Wu S, Dai X, Zhu Z, Fan D, Jiang S, Dong Y, et al. Reciprocal regulation of lncRNA MEF and c-Myc drives colorectal cancer tumorigenesis. Neoplasia. (2024) 49:100971. doi: 10.1016/j.neo.2024.100971
37. Song L, Li D, Gu Y, Wen Z, Jie J, Zhao D, et al. MicroRNA-126 targeting PIK3R2 inhibits NSCLC A549 cell proliferation, migration, and invasion by regulation of PTEN/PI3K/AKT pathway. Clin Lung Cancer. (2016) 17:e65–75. doi: 10.1016/j.cllc.2016.03.012
38. Li H, Jiao W, Song J, Wang J, Chen G, Li D, et al. circ-hnRNPU inhibits NONO-mediated c-Myc transactivation and mRNA stabilization essential for glycosylation and cancer progression. J Exp Clin Cancer Res. (2023) 42:313. doi: 10.1186/s13046-023-02898-5
39. Peng Z, Fang C, Yuan H, Zhu Y, Ren Z, Lu M, et al. miR-135b-5p promotes gastric carcinogenesis by targeting CLIP4-mediated JAK2/STAT3 signal pathway. Cell Signal. (2024) 122:111339. doi: 10.1016/j.cellsig.2024.111339
40. Deng M, Xu Y, Yao Y, Wang Y, Yan Q, Cheng M, et al. Circular RNA hsa_circ_0051246 acts as a microRNA-375 sponge to promote the progression of gastric cancer stem cells via YAP1. PeerJ. (2023) 11:e16523. doi: 10.7717/peerj.16523
41. Yi J, Ye Z, Xu H, Zhang H, Cao H, Li X, et al. EGCG targeting STAT3 transcriptionally represses PLXNC1 to inhibit M2 polarization mediated by gastric cancer cell-derived exosomal miR-92b-5p. Phytomedicine. (2024) 135:156137. doi: 10.1016/j.phymed.2024.156137
42. Qi F, Liu X, Wu H, Yu X, Wei C, Huang X, et al. Long noncoding AGAP2-AS1 is activated by SP1 and promotes cell proliferation and invasion in gastric cancer. J Hematol Oncol. (2017) 10:48. doi: 10.1186/s13045-017-0420-4
43. Naidoo J, Page DB, and Wolchok JD. Immune checkpoint blockade. Hematol Oncol Clin North Am. (2014) 28:585–600. doi: 10.1016/j.hoc.2014.02.002
44. Xiong L, Shan X, Ma H, Guo S, Liu J, Chen X, et al. First-line PD-1 blockade combined with chemotherapy for stage IV penile squamous cell carcinoma: A multicenter retrospective study. J Natl Compr Canc Netw. (2024) 23:e247074. doi: 10.6004/jnccn.2024.7074
45. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, and Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. (2018) 11:39. doi: 10.1186/s13045-018-0582-8
46. Wu Y, Zhou X, Wang J, Chen G, Chen J, Wang R, et al. Application of immune checkpoint inhibitors in immunotherapy for gastric cancer. Immunotherapy. (2023) 15:101–15. doi: 10.2217/imt-2022-0080
47. Kang Y, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. (2017) 390:2461–71. doi: 10.1016/s0140-6736(17)31827-5
48. Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. (2023) 24:1181–95. doi: 10.1016/s1470-2045(23)00515-6
49. Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, et al. Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. (2017) 66:794–801. doi: 10.1136/gutjnl-2015-310839
50. Hiraga T. Immunotherapy targeting PD−1/PD−L1: A potential approach for the treatment of cancer bone metastases. Int J Oncol. (2024) 64:35. doi: 10.3892/ijo.2024.5623
51. Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PloS One. (2017) 12:e0182692. doi: 10.1371/journal.pone.0182692
52. Sun C, Mezzadra R, and Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. (2018) 48:434–52. doi: 10.1016/j.immuni.2018.03.014
53. Wu Q, Jiang L, Li S, He Q, Yang B, and Cao J. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin. (2021) 42:1–9. doi: 10.1038/s41401-020-0366-x
54. Kwok G, Yau TC, Chiu JW, Tse E, and Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. (2016) 12:2777–89. doi: 10.1080/21645515.2016.1199310
55. Imazeki H, Kato K, and Boku N. Nivolumab treatment for the patients with gastric cancer-present and future. Gan To Kagaku Ryoho. (2019) 46:1513–23.
56. Perez HL, Cardarelli PM, Deshpande S, Gangwar S, Schroeder GM, Vite GD, et al. Antibody-drug conjugates: current status and future directions. Drug Discov Today. (2014) 19:869–81. doi: 10.1016/j.drudis.2013.11.004
57. Postow MA. Managing immune checkpoint-blocking antibody side effects. Am Soc Clin Oncol Educ Book. (2015) 76–83. doi: 10.14694/EdBook_AM.2015.35.76
58. Zak KM, Grudnik P, Guzik K, Zieba BJ, Musielak B, Dömling A, et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget. (2016) 7:30323–35. doi: 10.18632/oncotarget.8730
59. Xu Y, Poggio M, Jin H, Shi Z, Forester C, Wang Y, et al. Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nat Med. (2019) 25:301–11. doi: 10.1038/s41591-018-0321-2
60. Lim SO, Li C, Xia W, Cha J, Chan L, Wu Y, et al. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. (2016) 30:925–39. doi: 10.1016/j.ccell.2016.10.010
61. Kim GR and Choi JM. Current understanding of cytotoxic T lymphocyte antigen-4 (CTLA-4) signaling in T-cell biology and disease therapy. Mol Cells. (2022) 45:513–21. doi: 10.14348/molcells.2022.2056
62. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. (2011) 332:600–3. doi: 10.1126/science.1202947
63. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. (2017) 377:1345–56. doi: 10.1056/NEJMoa1709684
64. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. (2019) 381:1535–46. doi: 10.1056/NEJMoa1910836
65. Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, et al. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clin Cancer Res. (2010) 16:1662–72. doi: 10.1158/1078-0432.Ccr-09-2870
66. Mou P, Ge QH, Sheng R, Zhu TF, Liu Y, and Ding K. Research progress on the immune microenvironment and immunotherapy in gastric cancer. Front Immunol. (2023) 14:1291117. doi: 10.3389/fimmu.2023.1291117
67. Faghfuri E, Shadbad MA, Faghfouri AH, and Soozangar N. Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination. Immunotherapy. (2022) 14:475–88. doi: 10.2217/imt-2021-0285
68. Xie J, Fu L, and Jin L. Immunotherapy of gastric cancer: Past, future perspective and challenges. Pathol Res Pract. (2021) 218:153322. doi: 10.1016/j.prp.2020.153322
69. Högner A and Moehler M. Immunotherapy in gastric cancer. Curr Oncol. (2022) 29:1559–74. doi: 10.3390/curroncol29030131
70. Nakayama I and Shitara K. Cell-based therapies in GI cancers: current landscape and future directions. Am Soc Clin Oncol Educ Book. (2025) 45:e471716. doi: 10.1200/edbk-25-471716
71. Rosenberg SA, Spiess P, and Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. (1986) 233:1318–21. doi: 10.1126/science.3489291
72. Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, Lavorino C, et al. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy. (2012) 14:841–50. doi: 10.3109/14653249.2012.681038
73. Yamaue H, Tanimura H, Tsunoda T, Iwahashi M, Tani M, Inoue M, et al. Clinical application of adoptive immunotherapy by cytotoxic T lymphocytes induced from tumor-infiltrating lymphocytes. Nihon Gan Chiryo Gakkai Shi. (1990) 25:978–89.
74. Wang Y, Zhu C, Song W, Li J, Zhao G, and Cao H. PD-L1 expression and CD8(+) T cell infiltration predict a favorable prognosis in advanced gastric cancer. J Immunol Res. (2018) 2018:4180517. doi: 10.1155/2018/4180517
75. Gao X, Mi Y, Guo N, Xu H, Xu L, Gou X, et al. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol. (2017) 8:774. doi: 10.3389/fimmu.2017.00774
76. Liu G, Chen D, Zhao X, You X, Huang C, Cheng Z, et al. Efficacy of DC-CIK immunotherapy combined with chemotherapy on locally advanced gastric cancer. J Oncol. (2022) 2022:5473292. doi: 10.1155/2022/5473292
77. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res. (2006) 26:2237–42.
78. Jäkel CE, Vogt A, Gonzalez-Carmona MA, and Schmidt-Wolf IG. Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. (2014) 2014:897214. doi: 10.1155/2014/897214
79. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer. (2000) 88:577–83. doi: 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V
80. Shen D, Liu Z, Xu J, Xu F, Lin Q, Lin F, et al. Efficacy of adoptive cellular therapy in patients with gastric cancer: a meta-analysis. Immunotherapy. (2016) 8:971–81. doi: 10.2217/imt.16.10
81. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, and Milone MC. CAR-T cell immunotherapy for human cancer. Science. (2018) 359:1361–5. doi: 10.1126/science.aar6711
82. Depil S, Duchateau P, Grupp SA, Mufti G, and Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. (2020) 19:185–99. doi: 10.1038/s41573-019-0051-2
83. Labanieh L, Majzner RG, and Mackall CL. Programming CAR-T cells to kill cancer. Nat BioMed Eng. (2018) 2:377–91. doi: 10.1038/s41551-018-0235-9
84. Pous A, Notario L, Hierro C, Layos L, and Bugés C. HER2-positive gastric cancer: the role of immunotherapy and novel therapeutic strategies. Int J Mol Sci. (2023) 24:11403. doi: 10.3390/ijms241411403
85. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. (2008) 14:7624–34. doi: 10.1158/1078-0432.Ccr-08-1547
86. Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, et al. Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer. J Natl Cancer Inst. (2019) 111:409–18. doi: 10.1093/jnci/djy134
87. Qi C, Gong J, Li J, Liu D, Qin Y, Ge S, et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat Med. (2022) 28:1189–98. doi: 10.1038/s41591-022-01800-8
88. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, MaChado M, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol. (2018) 4:e180013. doi: 10.1001/jamaoncol.2018.0013
89. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. (2018) 19:1437–48. doi: 10.1016/s1470-2045(18)30739-3
90. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction. J Clin Oncol. (2016) 34:1448–54. doi: 10.1200/jco.2015.63.5995
91. Rijken A, Lurvink RJ, Luyer MDP, Nieuwenhuijzen GAP, van Erning FN, van Sandick JW, et al. The burden of peritoneal metastases from gastric cancer: A systematic review on the incidence, risk factors and survival. J Clin Med. (2021) 10:4482. doi: 10.3390/jcm10214882
92. Mir S, Venugopalan A, Zhang J, Nair NU, Sengupta M, Khanal M, et al. Persistence of activated anti-mesothelin hYP218 chimeric antigen receptor T cells in the tumour is associated with efficacy in gastric and colorectal carcinomas. Clin Transl Med. (2024) 14:e70057. doi: 10.1002/ctm2.70057
93. Bębnowska D, Grywalska E, Niedźwiedzka-Rystwej P, Sosnowska-Pasiarska B, Smok-Kalwat J, Pasiarski M, et al. CAR-T cell therapy-an overview of targets in gastric cancer. J Clin Med. (2020) 9:1894. doi: 10.3390/jcm9061894
94. Xu Z, Chen Y, Ma L, Chen Y, Liu J, Guo Y, et al. Role of exosomal non-coding RNAs from tumor cells and tumor-associated macrophages in the tumor microenvironment. Mol Ther. (2022) 30:3133–54. doi: 10.1016/j.ymthe.2022.01.046
95. Huang D, Chen J, Yang L, Ouyang Q, Li J, Lao L, et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nat Immunol. (2018) 19:1112–25. doi: 10.1038/s41590-018-0207-y
96. Li B, Liang L, Chen Y, Liu J, Wang Z, Mao Y, et al. Circ_0008287 promotes immune escape of gastric cancer cells through impairing microRNA-548c-3p-dependent inhibition of CLIC1. Int Immunopharmacol. (2022) 111:108918. doi: 10.1016/j.intimp.2022.108918
97. Zhang L, Xu J, Zhang X, Zhang Y, Wang L, Huang X, et al. The role of tumoral FOXP3 on cell proliferation, migration, and invasion in gastric cancer. Cell Physiol Biochem. (2017) 42:1739–54. doi: 10.1159/000479442
98. Hao Q, Li W, Zhang C, Qin X, Xue X, Li M, et al. TNF-α induced FOXP3-NFκB interaction dampens the tumor suppressor role of FOXP3 in gastric cancer cells. Biochem Biophys Res Commun. (2013) 430:436–41. doi: 10.1016/j.bbrc.2012.11.039
99. Li J, Liao X, Xiang Y, Yao A, Fan L, Li H, et al. MKL1/miR34a/FOXP3 axis regulates cell proliferation in gastric cancer. J Cell Biochem. (2019) 120:7814–24. doi: 10.1002/jcb.28056
100. Li J, Zhang H, Liu M, Xiang Y, Li H, Huang F, et al. miR-133a-3p/FOXP3 axis regulates cell proliferation and autophagy in gastric cancer. J Cell Biochem. (2020) 121:3392–405. doi: 10.1002/jcb.29613
101. Fang W, Shi C, Wang Y, Song J, and Zhang L. microRNA-128-3p inhibits CD4+ regulatory T cells enrichment by targeting interleukin 16 in gastric cancer. Bioengineered. (2022) 13:1025–38. doi: 10.1080/21655979.2021.2017566
102. Yuan X, Chen L, Li M, Dong P, Xue J, Wang J, et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX-2-dependent manner. Clin Immunol. (2010) 134:277–88. doi: 10.1016/j.clim.2009.10.005
103. Deng C, Huo M, Chu H, Zhuang X, Deng G, Li W, et al. Exosome circATP8A1 induces macrophage M2 polarization by regulating the miR-1-3p/STAT6 axis to promote gastric cancer progression. Mol Cancer. (2024) 23:49. doi: 10.1186/s12943-024-01966-4
104. Wei M, Gu Z, Zheng L, Zhao M, and Wang X. Long non-coding RNA GAS5 promotes natural killer cell cytotoxicity against gastric cancer by regulating miR-18a. Neoplasma. (2020) 67:1085–93. doi: 10.4149/neo_2020_191014N1034
105. Tang C, Yang J, Qin J, Wu H, Cui H, Ge L, et al. Regulation of the PD-1/PD-L1 axis and NK cell dysfunction by exosomal miR-552-5p in gastric cancer. Dig Dis Sci. (2024) 69:3276–89. doi: 10.1007/s10620-024-08536-0
106. Qin J, Yang J, Cui H, Feng C, and Liu A. Exosomal miR-552-5p Regulates the Role of NK Cells in EMT of Gastric Cancer via the PD-1/PD-L1 Axis. J Cancer. (2025) 16:406–16. doi: 10.7150/jca.102360
107. Li Y, Wang Z, Gao P, Cao D, Dong R, Zhu M, et al. CircRHBDD1 promotes immune escape via IGF2BP2/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer. J Transl Med. (2024) 22:704. doi: 10.1186/s12967-024-05498-9
108. Yan X, Luo Q, Zhou S, Pan W, Zhang L, Yang D, et al. MicroRNA-375 reverses the expression of PD-L1 by inactivating the JAK2/STAT3 signaling pathways in gastric cancer. Clin Res Hepatol Gastroenterol. (2021) 45:101574. doi: 10.1016/j.clinre.2020.10.015
109. Miao Z, Li J, Wang Y, Shi M, Gu X, Zhang X, et al. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation. Mol Cancer. (2023) 22:205. doi: 10.1186/s12943-023-01883-y
110. Zhang L, Chen J, Liu Y, Zhang Y, Hong L, Li X, et al. Identification of lncRNA dual targeting PD-L1 and PD-L2 as a novel prognostic predictor for gastric cancer. Front Oncol. (2024) 14:1341056. doi: 10.3389/fonc.2024.1341056
111. Wang J, Yu Z, Wang J, Shen Y, Qiu J, and Zhuang Z. LncRNA NUTM2A-AS1 positively modulates TET1 and HIF-1A to enhance gastric cancer tumorigenesis and drug resistance by sponging miR-376a. Cancer Med. (2020) 9:9499–510. doi: 10.1002/cam4.3544
112. Dang S, Malik A, Chen J, Qu J, Yin K, Cui L, et al. LncRNA SNHG15 contributes to immuno-escape of gastric cancer through targeting miR141/PD-L1. Onco Targets Ther. (2020) 13:8547–56. doi: 10.2147/ott.S251625
113. Guo T, Wang W, Ji Y, Zhang M, Xu G, and Lin S. LncRNA PROX1-AS1 Facilitates Gastric Cancer Progression via miR-877-5p/PD-L1 Axis. Cancer Manag Res. (2021) 13:2669–80. doi: 10.2147/cmar.S275352
114. Wang Y, Wang D, Xie G, Yin Y, Zhao E, Tao K, et al. MicroRNA-152 regulates immune response via targeting B7-H1 in gastric carcinoma. Oncotarget. (2017) 8:28125–34. doi: 10.18632/oncotarget.15924
115. Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, et al. The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1. Oncotarget. (2017) 8:21609–25. doi: 10.18632/oncotarget.15450
116. Shen J, Su X, Wang Q, Ke Y, Zheng T, Mao Y, et al. Current and future perspectives on the regulation and functions of miR-545 in cancer development. Cancer Pathog Ther. (2024) 2:142–54. doi: 10.1016/j.cpt.2023.09.001
117. Han H, Ding G, Wang S, Meng J, Lv Y, Yang W, et al. Long non-coding RNA LOC339059 attenuates IL-6/STAT3-signaling-mediated PDL1 expression and macrophage M2 polarization by interacting with c-myc in gastric cancer. Cancers (Basel). (2023) 15:5313. doi: 10.3390/cancers15225313
118. Li Z, Suo B, Long G, Gao Y, Song J, Zhang M, et al. Exosomal miRNA-16-5p derived from M1 macrophages enhances T cell-dependent immune response by regulating PD-L1 in gastric cancer. Front Cell Dev Biol. (2020) 8:572689. doi: 10.3389/fcell.2020.572689
119. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. (2009) 29:789–91. doi: 10.1161/atvbaha.108.179663
120. Zhang J, Pang X, Lei L, Zhang J, Zhang X, Chen Z, et al. LncRNA CRART16/miR-122-5p/FOS axis promotes angiogenesis of gastric cancer by upregulating VEGFD expression. Aging (Albany NY). (2022) 14:4137–57. doi: 10.18632/aging.204078
121. Du J, Liang Y, Li J, Zhao J, and Lin X. Gastric cancer cell-derived exosomal microRNA-23a promotes angiogenesis by targeting PTEN. Front Oncol. (2020) 10:326. doi: 10.3389/fonc.2020.00326
122. Qiu S, Xie L, Lu C, Gu C, Xia Y, Lv J, et al. Gastric cancer-derived exosomal miR-519a-3p promotes liver metastasis by inducing intrahepatic M2-like macrophage-mediated angiogenesis. J Exp Clin Cancer Res. (2022) 41:296. doi: 10.1186/s13046-022-02499-8
123. Wei Z, Chen L, Meng L, Han W, Huang L, and Xu A. LncRNA HOTAIR promotes the growth and metastasis of gastric cancer by sponging miR-1277-5p and upregulating COL5A1. Gastric Cancer. (2020) 23:1018–32. doi: 10.1007/s10120-020-01091-3
124. Han S, Wang Z, Liu J, Wang H, and Yuan Q. miR-29a-3p-dependent COL3A1 and COL5A1 expression reduction assists sulforaphane to inhibit gastric cancer progression. Biochem Pharmacol. (2021) 188:114539. doi: 10.1016/j.bcp.2021.114539
125. Baroni S, Romero-Cordoba S, Plantamura I, Dugo M, D’Ippolito E, Cataldo A, et al. Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis. (2016) 7:e2312. doi: 10.1038/cddis.2016.224
126. Zhang H, Deng T, Liu R, Ning T, Yang H, Liu D, et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. Mol Cancer. (2020) 19:43. doi: 10.1186/s12943-020-01168-8
127. Yang T, Yang X, Chen X, Wang X, Hua J, Zhou D, et al. MicroRNA-106b in cancer-associated fibroblasts from gastric cancer promotes cell migration and invasion by targeting PTEN. FEBS Lett. (2014) 588:2162–9. doi: 10.1016/j.febslet.2014.04.050
128. Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, et al. miR-205 hinders the Malignant interplay between prostate cancer cells and associated fibroblasts. Antioxid Redox Signal. (2014) 20:1045–59. doi: 10.1089/ars.2013.5292
129. Song J, Lin Z, Liu Q, Huang S, Han L, Fang Y, et al. MiR-192-5p/RB1/NF-κBp65 signaling axis promotes IL-10 secretion during gastric cancer EMT to induce Treg cell differentiation in the tumour microenvironment. Clin Transl Med. (2022) 12:e992. doi: 10.1002/ctm2.992
130. Deng C, Peng J, Yuan C, Li H, Li W, Chu H, et al. Comprehensive analysis to construct a novel immune-related prognostic panel in aging-related gastric cancer based on the lncRNA–miRNA-mRNA ceRNA network. Front Mol Biosci. (2023) 10:1163977. doi: 10.3389/fmolb.2023.1163977
131. Xu J, Wen J, Li S, Shen X, You T, Huang Y, et al. Immune-related nine-microRNA signature for predicting the prognosis of gastric cancer. Front Genet. (2021) 12:690598. doi: 10.3389/fgene.2021.690598
132. Zhao Z, Mak TK, Shi Y, Huang H, Huo M, and Zhang C. The DNA damage repair-related lncRNAs signature predicts the prognosis and immunotherapy response in gastric cancer. Front Immunol. (2023) 14:1117255. doi: 10.3389/fimmu.2023.1117255
133. Lei L, Li N, Yuan P, and Liu D. A new risk model based on a 11-m(6)A-related lncRNA signature for predicting prognosis and monitoring immunotherapy for gastric cancer. BMC Cancer. (2022) 22:365. doi: 10.1186/s12885-021-09062-2
134. Yu D, Zhang J, Wang M, Ji R, Qian H, Xu W, et al. Exosomal miRNAs from neutrophils act as accurate biomarkers for gastric cancer diagnosis. Clin Chim Acta. (2024) 554:117773. doi: 10.1016/j.cca.2024.117773
135. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. (2015) 25:981–4. doi: 10.1038/cr.2015.82
136. Xu B, Huang Y, Zheng E, Wang J, Zhang C, Geng X, et al. Hsa_circ_0072309 is a prognostic biomarker and is correlated with immune infiltration in gastric cancer. Heliyon. (2023) 9:e13191. doi: 10.1016/j.heliyon.2023.e13191
137. Shen Y, Lin J, Jiang T, Shen X, Li Y, Fu Y, et al. GC-derived exosomal circMAN1A2 promotes cancer progression and suppresses T-cell antitumour immunity by inhibiting FBXW11-mediated SFPQ degradation. J Exp Clin Cancer Res. (2025) 44:24. doi: 10.1186/s13046-025-03288-9
138. Anfossi S, Babayan A, Pantel K, and Calin GA. Clinical utility of circulating non-coding RNAs - an update. Nat Rev Clin Oncol. (2018) 15:541–63. doi: 10.1038/s41571-018-0035-x
139. Ding W, Sun P, Tan Y, Jiang H, Xi C, Zhuang L, et al. Construction of a prognostic immune-related lncRNA risk model for gastric cancer. J Oncol. (2022) 2022:5137627. doi: 10.1155/2022/5137627
140. Zheng X, Dong L, Wang K, Zou H, Zhao S, Wang Y, et al. MiR-21 participates in the PD-1/PD-L1 pathway-mediated imbalance of Th17/Treg cells in patients after gastric cancer resection. Ann Surg Oncol. (2019) 26:884–93. doi: 10.1245/s10434-018-07117-6
141. Miliotis C and Slack FJ. miR-105-5p regulates PD-L1 expression and tumor immunogenicity in gastric cancer. Cancer Lett. (2021) 518:115–26. doi: 10.1016/j.canlet.2021.05.037
142. Li X, Li Z, Liu P, Ai S, Sun F, Hu Q, et al. Novel circRNAs in hub ceRNA axis regulate gastric cancer prognosis and microenvironment. Front Med (Lausanne). (2021) 8:771206. doi: 10.3389/fmed.2021.771206
143. Kanasty R, Dorkin JR, Vegas A, and Anderson D. Delivery materials for siRNA therapeutics. Nat Mater. (2013) 12:967–77. doi: 10.1038/nmat3765
144. Shan H, Zhang X, Zhang X, Wei Y, Meng L, Li J, et al. CircSCUBE3 reduces the anti-gastric cancer activity of anti-PD-L1. Mol Biotechnol. (2024) 66:123–37. doi: 10.1007/s12033-023-00696-0
145. An L, Huo Y, Xiao N, Su S, and Wang K. SHP2 mediates the ROS/JNK/NFAT4 signaling pathway in gastric cancer cells prompting lncRNA SNHG18 to drive gastric cancer growth and metastasis via CAR-T cells. Heliyon. (2024) 10:e34008. doi: 10.1016/j.heliyon.2024.e34008
146. Chen D, Sheng H, Zhang D, Jin Y, Zhao B, Chen N, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer. (2021) 20:166. doi: 10.1186/s12943-021-01475-8
147. Guo Q, Wang X, Zhai Y, Dong Y, and He Q. Oxaliplatin activates P53/miR-34a/survivin axis in inhibiting the progression of gastric cancer cells. Immun Inflammation Dis. (2024) 12:e70004. doi: 10.1002/iid3.70004
148. Zhang F, Yin Y, Xu W, Zhou Z, Sun X, and Li P. Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR-616-5p/DUSP2 axis. Basic Clin Pharmacol Toxicol. (2021) 129:345–56. doi: 10.1111/bcpt.13641
149. Gupta S, Panda PK, Luo W, Hashimoto RF, and Ahuja R. Network analysis reveals that the tumor suppressor lncRNA GAS5 acts as a double-edged sword in response to DNA damage in gastric cancer. Sci Rep. (2022) 12:18312. doi: 10.1038/s41598-022-21492-x
Keywords: ncRNAs, gastric cancer, tumor immunity, immunotherapy, molecular mechanism
Citation: Dong H, Ye C, Yu X and Shao Y (2025) Non-coding RNAs in gastric cancer immunotherapy: mechanisms and clinical implications. Front. Immunol. 16:1688181. doi: 10.3389/fimmu.2025.1688181
Received: 18 August 2025; Accepted: 16 October 2025;
Published: 28 October 2025.
Edited by:
José Díaz-Chávez, Instituto Nacional de Cancerología (INCAN), MexicoCopyright © 2025 Dong, Ye, Yu and Shao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Haotian Dong, ZG9uZ2hhb3QwNjA5QDE2My5jb20=; Yongfu Shao, ZnlzaGFveW9uZ2Z1QG5idS5lZHUuY24=; c2hhb3lvbmdmdTExNzNAMTYzLmNvbQ==